“Partnering with Xceleron to bring our drug candidates into clinical development early in the development process provides Neurocrine with significant benefits in terms of or additional candidate selection as well as reduced risk and cost,” said Dr. Haig Bozigian, Neurocrine’s vice president of preclinical development. “While our lead compound is being evaluated in clinical studies, microdose studies will provide additional valuable comparative pharmacokinetics and bioavailability for our back-up compounds.”